Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-09-24
1993-10-26
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 424 9463, 424 9464, 435215, 435216, 530350, A61K 3702, A61K 37547, C12N 972, C07K 1300
Patent
active
052566420
ABSTRACT:
The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention further relates to methods for treating thrombotic conditions in humans and animals by administering a composition comprising soluble CR1 and a thrombolytic agent. In particular, the compositions and methods are useful both for reducing reperfusion injury and ameliorating the other effects of myocardial infarction.
REFERENCES:
patent: 4285932 (1981-08-01), Smith
patent: 4642284 (1987-02-01), Cooper et al.
patent: 4672044 (1987-06-01), Schreiber
patent: 4761371 (1988-08-01), Bell et al.
patent: 4808405 (1989-02-01), Smith
patent: 4883784 (1989-11-01), Kaneko
patent: 5143901 (1992-09-01), Schwarz et al.
Krych et al., 1989, A secreted small form of human complement C3b/C4b receptor (CR1) that binds to C4b but not C3b, F.A.S.E.B. J. 3:A368.
Chung and Reid, 1985, Structural and functional studies on C4b-binding protein, a regulatory component of the human complement system, Bioscience Reports 5:255-865.
Andreatta et al. (Chemical Abstracts vol. 94(21), p. 303, abstract 170110u; 1980, in Enzyme Inhibitors, Proc. Meet., Brodbeck, U.(ed), Verlag Chem., pp. 261-272).
Iida and Nussenzweig (1981, J. Exp. Med. 153:1138-1150).
Medof et al. (1983, Ann. N.Y. Acad. Sci. 421:299-306).
Atkinson and Jones (1984, J. Clin. Invest. 74:1649-1657).
Yoon and Fearon (1985, J. Immunol. 134:3332-3338).
Seya et al. (1985, J. Immunol. 135:2661-2667).
Fries et al. (1985, J. Immol. 135:2673-2679).
Wong et al. (1985, J. Immunol. Meth. 82:303-313).
Holers et al. (1987, Proc. Natl. Acad. Sci. U.S.A. 84:2459-2463).
Klickstein et al. (1987a, J. Exp. Med. 165:1095-1112).
Hourcade et al. (1987a, Abstracts: XIIth Int. Complement Workshop, Arlaud et al. (eds.), pp. 171-172, Abstract 128).
Hourcade et al. (1987b, ibid, p. 172, Abstract 129).
Klickstein et al. (1987b, ibid, p. 180, Abstract 149).
Wilson et al. (Chemical Abstracts vol. 108(1), p. 421, abstract 4304y; 1987, Immunol. Res. 6:192-209).
Frank (1987, New Eng. J. Med. 316:1525-1530).
Hourcade et al. (1988, J. Exp. Med. 168:1255-1270).
Klickstein et al. (1988, J. Exp. Med. 168:1699-1717).
Kumar et al. (1989, Biochem. 28:4040-4046).
Dahlback et al. (1983, Proc. Natl. Acad. Sci. U.S.A. 80:3461-3465).
Chung et al. (1985, Biochem. J. 230:133-141).
Wong and Fearon (1985, J. Immunol. 134:4048-4056).
Matzner et al. (Chemical Abstracts vol. 106(1), abstract 3626b, 1986, J. Cell. Physiol. 129:215-220).
Kristensen et al. (1987, Biochem. 26:4668-4674).
Glover et al. (1988, Mol. Immunol. 25:1261-1267).
Schasteen et al. (1988, Mol. Immunol. 25:1269-1275).
Stenlund et al. (1983, EMBO J. 2:669-673).
McCluskey et al. (1985, Cell 40:247-257).
Hiraki et al. (1986, J. Immunol. 136:4291-4296).
Weisman et al. (1990, Science 249:146-151).
Weis et al. (1987, J. Immunol. 138:312-315).
Wong et al. (1985, Proc. Natl. Acad. Sci. USA 82:7711-7715).
Sim (1985, Biochem. J. 232:883-889).
Dykman et al. (1983, Proc. Natl. Acad. Sci. U.S.A. 80:1698-1702).
Iida et al. (1982, J. Exp. Med. 155:1427-1438).
Fearon (1979, Proc. Natl. Acad. Sci. U.S.A. 16:5867-5871).
Weis et al. (1986, Proc. Natl. Acad. Sci. USA 83:5639-5643).
Young and Davis (1983, Science 222:778-782).
Suggs et al. (1981, Proc. Natl. Acad. Sci. USA 78:6613-6617).
Hewick et al. (1981, J. Biol. Chem. 256:7990-7997.).
Smith et al. (1987, Science 238:1704-1707).
Carson Gerald R.
Concino Michael F.
Fearon Douglas T.
Ip Stephen H.
Klickstein Lloyd B.
Brigham and Women's Hospital
T Cell Sciences, Inc.
The Johns Hopkins University
Walsh Stephen
Wax Robert A.
LandOfFree
Compositions of soluble complement receptor 1 (CR1) and a thromb does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of soluble complement receptor 1 (CR1) and a thromb, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of soluble complement receptor 1 (CR1) and a thromb will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-959461